FEB 11, 2016 3:22 PM PST

Treating TTP with Synthetic Antibodies

WRITTEN BY: Kara Marker
Rare but deadly, thrombotic thrombocytopenic purpura (TTP) is a disease where blood clots block the smallest blood vessels often leading to kidney failure, stroke, and heart disease. Over 4 million Americans are affected each year, either from hereditary or acquired forms of the disease.
 
Past the acute phase, TTP is relatively easily defeated with immunotherapy, said Paul Knöbl from the Medical University of Vienna. However, 10 to 20 percent of people do not survive the acute phase, even with plasma exchange therapy. In a new study published in the New England Journal of Medicine, Knöbl and other researchers from the Medical University of Vienna examined the capability of a synthesized antibody to reverse the impact of the disease.
 
Newly formed blood vessel within an occluded artery of the lower leg

 
TTP is characterized by a deficiency of an enzyme called ADAMST13 regardless of whether the disease was acquired or inherited. Without ADAMST13, another protein called von Willebrand is overexpressed and destructively so, binding platelets and inducing aggregation in blood vessels. Blood clots caused by TTP can lead to kidney failure, stroke, and heart disease.
 
Current plasma exchange therapy removes autoantibodies causing the ADAMST13 deficiency, removes overgrown von Willebrand protein complexes, and replenishes the body’s stock of ADAMST13. After a patient survives the acute phase, immunotherapy prevents continuous autoantibody formation. The synthesized antibody proposed by this study would be used for treatment both during and after the acute phase, instead targeting the masses of overactive von Willebrand protein. By blocking the protein’s interaction with platelets, the antibody reduces the severity of blood clots characterizing TTP to practically zero.
 
"In future this drug might also be used to treat similar diseases, which are jointly caused by overactivity of the von Willebrand factor, and therefore represents a new treatment option," said the Medical University of Vienna’s Bernd Jilma.
 
The antibody being studied is called “caplacizumab.”
 

Source: Medical University of Vienna, New England Journal of Medicine
 
About the Author
  • I am a scientific journalist and enthusiast, especially in the realm of biomedicine. I am passionate about conveying the truth in scientific phenomena and subsequently improving health and public awareness. Sometimes scientific research needs a translator to effectively communicate the scientific jargon present in significant findings. I plan to be that translating communicator, and I hope to decrease the spread of misrepresented scientific phenomena! Check out my science blog: ScienceKara.com.
You May Also Like
APR 01, 2021
Health & Medicine
Flavanol-rich Foods Protect Heart from Stress
APR 01, 2021
Flavanol-rich Foods Protect Heart from Stress
Drinking hot cocoa is comforting on cold winter nights, and new research from the University of Birmingham shows that it ...
APR 13, 2021
Cardiology
Can a Ketosis Metabolite Act as a Biomarker for Cardiovascular Diseases?
APR 13, 2021
Can a Ketosis Metabolite Act as a Biomarker for Cardiovascular Diseases?
Quick and reliable diagnostics are the key to controlling many diseases, including cardiovascular disease. Biomarkers ar ...
JUL 13, 2021
Health & Medicine
The Science of Crying
JUL 13, 2021
The Science of Crying
Crying: In humans, it's the production of tears usually accompanied by facial muscle contractions and vocal sounds. ...
AUG 12, 2021
Cardiology
Benefits of Plant-Based Diets Demonstrated in Long-Term Study
AUG 12, 2021
Benefits of Plant-Based Diets Demonstrated in Long-Term Study
New research has confirmed studies that have indicated how beneficial a diet rich in nutritious foods like fruits, veget ...
AUG 25, 2021
Cardiology
Don't Underestimate the Importance of the Spleen
AUG 25, 2021
Don't Underestimate the Importance of the Spleen
The spleen is one of the organs we can live without, but researchers are increasingly recognizing its importance. We kno ...
SEP 02, 2021
Cancer
When Cholesterol Doesn't Kill Cancer, it Makes it Stronger!
SEP 02, 2021
When Cholesterol Doesn't Kill Cancer, it Makes it Stronger!
High cholesterol is associated with an increased risk of several types of cancer, and cancer patients with high choleste ...
Loading Comments...